Molecular testing for relapsed small cell lung cancer
Part of Cancer clinical trials.
This study uses tumor tissue to look for molecular (biologic) changes after your small cell lung cancer comes back. It may help doctors choose the most appropriate next treatment based on what the cancer’s biology shows.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must give informed consent before any study steps
- You are at least 20 years old
- You have confirmed small cell lung cancer from biopsy or test results
- Your health/activity level is about normal to limited (ECOG 0–2)
- Your cancer was treated with platinum chemotherapy as the first treatment, or is currently being treated this way
- You must have tumor tissue available for molecular testing, or be willing to have a new biopsy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special immune cell therapy (CAR T cells) that targets a protein called B7-H3 on your cancer cells. It is for people with small cell lung cancer or similar neuroendocrine cancers that have returned or not responded to standard treatments.
This trial tests a new drug, NMS-03305293, in adults with small cell lung cancer that has come back after earlier treatments. The goal is to see if it can help shrink or slow the cancer.
This trial is for adults with small cell lung cancer where your diagnosis is confirmed by a tissue test. The study looks at molecular (tumor-level) features to help guide treatment choices that may fit you better.
This study looks at blood and tissue samples from people with small cell lung cancer that has returned. The goal is to learn more about the cancer and how to better treat it.
This trial collects blood and tumor samples from people newly diagnosed with small cell lung cancer to study how genetic markers can predict treatment success and monitor disease over time.
This trial tests a chemotherapy drug called nab-paclitaxel combined with other local treatments (like radiation) for people with small cell lung cancer that has returned after initial treatment. The goal is to see if this combination helps control the cancer and improves outcomes.
Hear when a new Neuroendocrine Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.